na-931
Body Weight Changes
Biomed Industries, Inc.Phase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Body Weight Changes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dolutegravir Augusta University | Phase 4 | BB |
Ertugliflozin Getz Pharma | Phase 4 | BB |
(±)-FTC Prism Health North Texas | Phase 3 | B |
Bictegravir Prism Health North Texas | Phase 3 | B |
Doravirine Prism Health North Texas | Phase 3 | B |
View all 15 →
Same molecule, other indications
na-931 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →